Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $326.13M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.75M
Average 0.81M
IRD Total Current Liabilities
All obligations due within one year.
Opus Genetics, Inc.NASDAQ: IRD
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities falls 61.5% from a year ago
Total current liabilities stood at $9.34M at the end of Q1 FY2026, down 61.5% from a year earlier and up 20.0% from the prior quarter. Over 3 fiscal years it compounded at +41.4% a year.
Context
- Total current liabilities amounted to 14.0% of total assets at the end of Q1 FY2026, down 36.4 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -61.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 7.78M USD
- Year-over-year change
- -31.1%
- 4-year CAGR
- +19.2%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.78M | -31.1% |
| FY2024 | 2024-12-31 | 11.3M | +179.4% |
| FY2023 | 2023-12-31 | 4.04M | +46.8% |
| FY2022 | 2022-12-31 | 2.75M | -28.6% |
| FY2021 | 2021-12-31 | 3.86M | — |
Total Current Liabilities vs competitors
How IRD compares with its peers on the latest reported figures
- IRD's Mar 2026 total current liabilities of $9.34M is the 7th highest of the 10 companies compared; the peer median is $19.34M.
- Its year-over-year change of -61.5% is the 9th highest of 10, against a peer median of -22.4%.
- Total current liabilities amounts to 14.0% of total assets for IRD, versus a peer median of 17.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $249.24M | +19.7% | +19.6% | 133.7% | |
| Mar 2026 | $40.97M | -62.7% | -9.5% | 17.1% | |
| Mar 2026 | $37.92M | +38.8% | -23.3% | 76.2% | |
| Mar 2026 | $29.23M | +51.3% | +56.6% | 21.9% | |
| Mar 2026 | $19.34M | -38.2% | -39.1% | 16.4% | |
| Mar 2026 | $10.24M | -22.4% | +7.6% | 3.8% | |
IRDOpus Genetics, Inc. | Mar 2026 | $9.34M | -61.5% | +41.4% | 14.0% |
| Mar 2026 | $6.07M | +26.9% | +27.3% | 20.4% | |
| Mar 2026 | $6.05M | -44.7% | +21.3% | 16.7% | |
| Mar 2026 | $4.72M | -34.7% | -47.1% | 2.4% | |
| Peer median (excluding IRD) | $19.34M | -22.4% | +7.6% | 17.1% | |
Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Opus Genetics, Inc.
NASDAQ:IRD
Intrinsic Alpha fair value
Locked
Current Price
$3.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.